论文部分内容阅读
目的 观察拉莫三嗪 (LTG)添加治疗癫长期开放性观察的临床疗效和安全性。方法 据添加LTG前 3个月基线月均发作频率 ,将 94例癫患者分为非难治性癫组 5 8例 (NIE组 )和难治性癫组 3 6例 (IE组 ) ,将每例最后 6个月的月均发作频率与基线进行比较 ,并观察其副反应。结果 总有效率为 69 1%。NIE组有效率 (84 5 % )、控制率 (63 8% )较IE组 (4 4 4% ,2 2 2 % )明显为高。IE组的疗效与我们均期 1年的观察结果近似。LTG与丙戊酸 (VPA)配伍应用 ,疗效较好 ,且可以减少LTG的剂量。副反应主要为皮疹 (12 8% )。结论 LTG添加治疗癫疗效稳定 ,耐药性、副反应少 ,是适于长期应用的新的高效抗癫药物之一。
Objective To observe the clinical efficacy and safety of lamotrigine (LTG) in the treatment of long-term open epileptic seizures. Methods According to the baseline monthly mean seizure frequency of LTG in the first 3 months, 94 epileptic patients were divided into 58 non-refractory epilepsy group (NIE group) and 36 refractory epilepsy group (IE group) The average monthly seizure frequency of the last 6 months in each case was compared with the baseline and its side effects were observed. The total effective rate of 69 1%. In the NIE group, the effective rate (84.5%) and control rate (63.8%) were significantly higher than those in the IE group (44.4%, 22.2%). The efficacy of the IE group was similar to our 1-year observation period. LTG and valproic acid (VPA) compatibility and application, good effect, and can reduce the dose of LTG. Side effects mainly rash (12 8%). CONCLUSION: LTG is a new and effective anti-epileptic drug suitable for long-term use in the treatment of epilepsy with stable efficacy, less drug resistance and fewer side effects.